Achilles therapeutics to present at the 10th annual immuno-oncology 360 conference

London, feb. 05, 2024 (globe newswire) -- achilles therapeutics plc (nasdaq: achl), a clinical-stage biopharmaceutical company developing ai-powered precision t cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the company will be presenting at the following conference:
ACHL Ratings Summary
ACHL Quant Ranking